bpc-157 safety human trials FDA advisory committee votes to add popular peptide to drug compounding list BPC-157 – No Proof Required!

Question: I know there isn't a one universal answer to this, but I do know there is a norm and I want to know it so I don't hurt myself

No confirmed evidence from published studies demonstrates that BPC-157 causes cancer, though its angiogenic mechanism creates a theoretical risk of accelerating growth in pre-existing tumors through increased vascular supply

Risk-benefit analysis should consider the severity and impact of the condition being treated, failure or limitations of conventional therapies, individual patient risk factors particularly for malignancy, and patient preferences regarding experimental treatments

You may see modest weight reduction after 4-8 weeks when combined with proper diet and exercise

Cysteamine-colon and cysteamine-duodenum lesions in rats